To conclude, the molecular assessment of SNU1544 and LS174T 3D tumor lysates indicated that treatments with 177Lu-DOTA-M5A and/or onalespib could possibly restore SMAD3 expression in the TGF-β pathway. The gene discussed is SMAD3; the disease is neoplasm.